Systemic treatment of Darier's disease with an oral retinoic acid derivative Ro 10-9359 Tigason.
In an open trial, seven patients with Darier's disease took part in a three month study to evaluate the effect of a new oral synthetic retinoid. Ro 10-9359 (Tigason). The usual dose was 50 mg daily. At two-week intervals, lesions were graded with respect to their nature, erythema, keratosis, and percent of body surface area involved. All but one patient, were markedly improved on the drug, and showed a marked preference for the retinoid above other treatments. No patients withdrew because of side-effects but all suffered dry lips. Other side-effects were mild or moderate and well tolerated. It is concluded that Tigason is effective in Darier's disease.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D007644:Darier Disease / Q000175:diagnosis / Q000188:drug therapy*; D005050:Etretinate / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D014212:Tretinoin / Q000031:analogs & derivatives*
D014212:Tretinoin; D005050:Etretinate